Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
56
Recruiting, any sponsor type, condition "myasthenia gravis"
By trial status
The same filters, counted in each status. Pick one to switch.
56 trials
Showing 1 to 25, recently updated first.
AstraZenecaAstraZeneca (AZN)
NCT06909253 · 50 participants (planned) · Start May 15, 2025 · Primary completion Dec 31, 2029
Drug: Ravulizumab · For: Myasthenia Gravis, Generalized
Sites: Bydgoszcz, Poland; Gdansk, Poland; Katowice, Poland · 11 sites in all
argenxargenx (ARGX)
NCT06909214 · 35 participants (planned) · Start Apr 17, 2025 · Primary completion Jul 8, 2026
Drug: Efgartigimod PH20 SC · For: New Onset Generalized Myasthenia Gravis (gMG)
Sites: La Jolla, California; Rancho Mirage, California; Boca Raton, Florida · 18 sites in all
- Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)Pivotal-lookingRecruiting
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyIndustry
NCT06463587 · 264 participants (planned) · Start Jun 25, 2024 · Primary completion Aug 23, 2028
Drug: Cladribine Low Dose; Cladribine High Dose · For: Generalized Myasthenia Gravis
Sites: Phoenix, Arizona; Longmont, Colorado; Farmington, Connecticut · 159 sites in all
Kite, A Gilead CompanyGilead Sciences (GILD)
NCT07304154 · 57 participants (planned) · Start Apr 10, 2026 · Primary completion Dec 2031
Drug: KITE-363; Fludarabine and 1 more · For: Chronic Inflammatory Demyelinating Polyneuropathy; Myasthenia Gravis; Multiple Sclerosis
Sites: Newport Beach, California; Palo Alto, California; New York, New York · 10 sites in all
argenxargenx (ARGX)
NCT07673627 · 40 participants (planned) · Start Jul 10, 2026 · Primary completion Oct 2027
Drug: Empasiprubart IV · For: AChR-Ab Seropositive Generalized Myasthenia Gravis; Myasthenia Gravis (MG); MG - Myasthenia Gravis and 1 more
Sites: Carlsbad, California; Miami, Florida; Tampa, Florida · 19 sites in all
- A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod AlfaRecruiting
argenxargenx (ARGX)
NCT06298565 · 680 participants (planned) · Start Nov 4, 2024 · Primary completion Jun 2034
Drug: efgartigimod · For: Myasthenia Gravis
Sites: San Francisco, California; Boca Raton, Florida; Jacksonville Beach, Florida · 36 sites in all
- Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia GravisPivotal-lookingRecruiting
Immunovant Sciences GmbHIndustry
NCT07039916 · 231 participants (planned) · Start May 27, 2025 · Primary completion Dec 2027
Drug: IMVT-1402; IMVT-1402 and 2 more · For: Generalized Myasthenia Gravis
Sites: Huntsville, Alabama; Mobile, Alabama; Phoenix, Arizona · 93 sites in all
- A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia GravisPivotal-lookingRecruiting
NCT07463521 · 120 participants (planned) · Start May 27, 2026 · Primary completion Dec 1, 2028
Drug: Rozanolixizumab; Placebo · For: Ocular Myasthenia Gravis
Sites: Scottsdale, Arizona; O'Fallon, Illinois; Amherst, New York · 36 sites in all
- A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia GravisPivotal-lookingRecruiting
NCT07465289 · 100 participants (planned) · Start Sep 16, 2026 · Primary completion Mar 17, 2031
Drug: Rozanolixizumab · For: Ocular Myasthenia Gravis
Sites: Scottsdale, Arizona; Columbus, Ohio; Beijing, China · 18 sites in all
- A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia GravisPivotal-lookingRecruiting
NCT06055959 · 8 participants (planned) · Start Oct 16, 2024 · Primary completion May 12, 2027
Drug: Zilucoplan · For: Generalized Myasthenia Gravis
Sites: Chicago, Illinois; Denton, Texas; Milan, Italy · 9 sites in all
- A Study of Nipocalimab Administered to Adults With Generalized Myasthenia GravisPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04951622 · 199 participants (planned) · Start Jul 15, 2021 · Primary completion Nov 17, 2023
Drug: Nipocalimab; Placebo and 1 more · For: Myasthenia Gravis
Sites: Paradise Valley, Arizona; Scottsdale, Arizona; Los Angeles, California · 112 sites in all
- A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia GravisPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05265273 · 12 participants (planned) · Start Jul 20, 2022 · Primary completion Jun 30, 2027
Drug: Nipocalimab · For: Myasthenia Gravis
Sites: Phoenix, Arizona; Los Angeles, California; Palo Alto, California · 19 sites in all
- Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia GravisPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07217587 · 115 participants (planned) · Start Jan 5, 2026 · Primary completion Sep 28, 2027
Drug: Nipocalimab; Efgartigimod · For: Myasthenia Gravis
Sites: Fullerton, California; Pomona, California; Colorado Springs, Colorado · 31 sites in all
- A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)Pivotal-lookingRecruiting
Dianthus TherapeuticsIndustry
NCT07647510 · 195 participants (planned) · Start Jun 29, 2026 · Primary completion Dec 2028
Drug: Claseprubart; Placebo · For: Myasthenia Gravis, Generalized
Sites: Pasadena, California; Boca Raton, Florida; Fayetteville, North Carolina · 12 sites in all
- A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)Pivotal-lookingRecruiting
TG Therapeutics, Inc.Industry
NCT07673744 · 120 participants (planned) · Start Nov 1, 2026 · Primary completion Jul 1, 2028
Drug: Ublituximab; Placebo · For: Myasthenia Gravis
Sites: Colorado Springs, Colorado; Clearwater, Florida; Maitland, Florida · 7 sites in all
TG Therapeutics, Inc.Industry
NCT06680037 · 100 participants (planned) · Start May 6, 2025 · Primary completion Dec 1, 2026
Drug: Azercabtagene zapreleucel (azer-cel) · For: B-cell Mediated Autoimmune Disorders
Sites: La Jolla, California; Ann Arbor, Michigan; Omaha, Nebraska · 8 sites in all
argenxargenx (ARGX)
NCT07294170 · 70 participants (planned) · Start Dec 19, 2025 · Primary completion Mar 7, 2028
Drug: Efgartigimod IV; Empasiprubart IV and 1 more · For: Myasthenia Gravis; MG; gMG and 3 more
Sites: Carlsbad, California; Miami, Florida; Tampa, Florida · 37 sites in all
AmgenAmgen (AMGN)
NCT06987539 · 15 participants (planned) · Start Jul 21, 2026 · Primary completion Mar 13, 2030
Drug: Inebilizumab · For: Generalized Myasthenia Gravis
Sites: Chicago, Illinois; Philadelphia, Pennsylvania; Austin, Texas · 14 sites in all
- Efgartigimod in IVIG Dependent Myasthenia Gravis PatientsPivotal-lookingRecruiting
Clinique Neuro-OutaouaisAcademic, hospital or other
NCT06765161 · 30 participants (planned) · Start Feb 6, 2025 · Primary completion Jan 6, 2027
Drug: efgartigimod administration · For: Myasthaenia Gravis
Sites: Gatineau, Canada
- Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related DiseasesRecruiting
Kite, A Gilead CompanyGilead Sciences (GILD)
NCT06626919 · 30 participants (planned) · Start Apr 30, 2025 · Primary completion Oct 2028
Drug: anito-cel; Cyclophosphamide and 1 more · For: Muscular Diseases; Neuromuscular Manifestations; Autoimmune and 4 more
Sites: Los Angeles, California; Orange, California; Palo Alto, California · 14 sites in all
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07622342 · 60 participants (planned) · Start Aug 28, 2026 · Primary completion Sep 2027
Drug: SHR-2173 injection; SHR-2173 injection and 1 more · For: Generalized Myasthenia Gravis
Sites: Changsha, China; Shanghai, China
- Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)Pivotal-lookingRecruiting
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT07596784 · 20 participants (planned) · Start Jul 27, 2026 · Primary completion Aug 24, 2027
Drug: Ravulizumab · For: Generalized Myasthenia Gravis; gMG
Sites: Beijing, China; Changchun, China; Fuzhou, China · 10 sites in all
Cabaletta BioIndustry
NCT06359041 · 24 participants (planned) · Start Dec 17, 2024 · Primary completion Sep 2029
Drug: CABA-201; CABA-201 · For: Generalized Myasthenia Gravis (gMG)
Sites: Orange, California; Sacramento, California; San Francisco, California · 17 sites in all
Tianjin Medical University General HospitalAcademic, hospital or other
NCT07022197 · 27 participants (planned) · Start Apr 10, 2025 · Primary completion Dec 30, 2027
Drug: BAFF-R CART · For: Chronic Inflammatory Demyelinating Polyradiculoneuropathy; NMO Spectrum Disorder; Myasthenia Gravis and 1 more
Sites: Tianjin, China
- A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia GravisPivotal-lookingRecruiting
argenxargenx (ARGX)
NCT06392386 · 12 participants (planned) · Start Jun 28, 2024 · Primary completion Sep 2027
Drug: Efgartigimod PH20 SC · For: Generalized Myasthenia Gravis
Sites: Charlotte, North Carolina; Denton, Texas; Charlottesville, Virginia · 22 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.